Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder Clinical Trial

Official title:

A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01430754
• Other study ID #: VP-VEC-162-3203
• Status: Completed
• Phase: Phase 3
• First received: August 30, 2011
• Last updated: October 8, 2014
• Start date: September 2011
• Est. completion date: December 2012

Study information

• Verified date: October 2014
• Source: Vanda Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.

Description:

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier is < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping. As time progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals moves further and further away from the 24-hour light-dark cycle and gradually, these individuals are unable to sleep at night and as a result experience extreme sleepiness during the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake time moves back into alignment with the social time for sleep and the individuals sleep well at night and have decreased daytime napping. The alignment between their endogenous circadian rhythms and the 24-hour day is temporary as they are continually drifting later and later each day.

This will be a multicenter, randomized withdrawal, double-masked, placebo-controlled, parallel study. The study has three phases: the tasimelteon run-in phase, the tau estimation phase, and the randomized withdrawal phase. Subjects who have participated in study VP-VEC-162-3201 that meet the entry criteria for this study will be eligible for the run-in phase The run-in phase comprises a screening visit where subject's initial eligibility will be evaluated. Subjects that meet the inclusion/exclusion criteria at screening will enter the run-in phase and will be dosed with 20 mg of tasimelteon daily for 6 weeks. The tau estimation phase (48 hour urine collection samples to evaluate response to tasimelteon) will follow the run-in phase and will last approximately 6 weeks long. The randomized withdrawal phase comprises approximately eight weeks of treatment with either placebo or tasimelteon 20 mg taken approximately 1 hour prior to their target bedtime in a double-masked fashion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Ability and acceptance to provide informed consent;

2. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and must have a negative pregnancy test at the screening and baseline visits; Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose.

3. Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;

4. Diagnosis of N24HSWD in a previous clinical trial as measured by a tau value of > 24.1 and the lower bound of the 95% CI is > 24.

Exclusion Criteria:

1. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;

2. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;

3. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 2 drinks/day or > 14 drinks/week);

a. Note: A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol or

• 12-ounces of beer

• 8-ounces of malt liquor

• 5-ounces of wine

• 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey);

4. Subject is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;

5. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;

6. Subjects who have estimated creatinine clearance (CLcr; based on the Cockcroft-Gault equation) = to 55 mL/min;

7. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening as determined by the clinical investigator;

8. Indication of impaired liver function (values for AST, ALT or bilirubin > 2 times Upper Limit of Normal);

9. Pregnant or lactating females;

10. A positive test for drugs of abuse at the screening visit; Note: A positive drug screen at Visit 1 needs to be discussed with the medical monitor and will be evaluated on a case-by-case basis.

11. Smoke more than 10 cigarettes/day;

12. Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;

13. Unwilling or unable to follow the medication restrictions described in Section 8.2., or unwilling or unable to sufficiently wash-out from use of a restricted medication

14. Unable to perform calls to the study IVR system to report questionnaire results;

15. Any other sound medical reason as determined by the clinical investigator;

16. Legal incompetence or limited legal competence, detainment in an institution for official or legal reasons.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Non-24-Hour Sleep-Wake Disorder
• Sleep Disorders, Circadian Rhythm

Intervention

Drug:
• tasimelteon
20 mg tasimelteon capsules, daily
• Placebo
Placebo capsules, daily

Locations

Country	Name	City	State
United States	Michigan Head-Pain Neurological Institute	Ann Arbor	Michigan
United States	Sleep Disorders Center Of Georgia	Atlanta	Georgia
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	PAB Clinical Research Inc.	Brandon	Florida
United States	St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)	Chesterfield	Missouri
United States	The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)	Chevy Chase	Maryland
United States	SleepMed, Inc. - Columbia	Columbia	South Carolina
United States	Radiant Research - Denver	Denver	Colorado
United States	Ohio Sleep Medicine Institute (Columbus Metropolitan Area)	Dublin	Ohio
United States	Suburban Lung Associates SC	Elk Grove Village	Illinois
United States	Todd J. Swick, M.D., P.A.	Houston	Texas
United States	Mercy Fitzgerald Hospital - Sleep Disorders Center (Philadelphia Metropolitan Area)	Lafayette Hill	Pennsylvania
United States	Kendall South Medical Center, Inc.	Miami	Florida
United States	New York Eye and Ear Infirmary	New York	New York
United States	Lynn Health Science Institute	Oklahoma city	Oklahoma
United States	SDS Clinical Trials Inc.	Orange	California
United States	Ocean Sleep Disorders Center - Ormond Beach	Ormond Beach	Florida
United States	VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)	Palo Alto	California
United States	Pulmonary Associates, PA	Phoenix	Arizona
United States	Consolidated Clinical trials	Pittsburgh	Pennsylvania
United States	Columbia Research Group Inc.	Portland	Oregon
United States	St. Johns Sleep Disorder Center - St. Johns Medical Plaza	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Vanda Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.	Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (t) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline t value = 24.1 or the lower bound of the 95% CI >24.0.	Approximately 12 weeks	No
Secondary	Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD	Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (t) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline t value = 24.1 or the lower bound of the 95% CI >24.0.	Approximately 12 weeks	No
Secondary	Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase	LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.	Approximately 12 weeks	No
Secondary	Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase	UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.	Approximately 12 weeks	No
Secondary	Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase	Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.	Approximately 12 weeks	Yes
Secondary	Change From Run-In in Circadian Time to Relapse During the Randomized Phase	Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.	Approximately 8 weeks	No